Saltar al contenido
Merck

04273

Sigma-Aldrich

Fosfato de sodio dibasic dodecahydrate

meets analytical specification of Ph. Eur., BP, E339, 98.5-102.5% (T)

Sinónimos:

Fosfato de sec-sodio, Fosfato de disodio, Hidrogenofosfato de disodio dodecahydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula lineal:
Na2HPO4 · 12H2O
Número de CAS:
Peso molecular:
358.14
Número CE:
Número MDL:
Código UNSPSC:
12161700
ID de la sustancia en PubChem:
NACRES:
NA.25

Agency

meets analytical specifications of BP
meets analytical specifications of Ph. Eur.

Nivel de calidad

Análisis

98.5-102.5% (T)

formulario

crystals

calidad

meets analytical specification of Ph. Eur., BP, E339

impurezas

reducing matter, complies
residual solvents, complies
≤0.001% heavy metals (as Pb)
≤1.0% NaH2PO4
57-61% water (Karl Fischer)

pérdida

57-61% loss on drying

pH

8.4-9.6 (20 °C, 1%)

trazas de anión

chloride (Cl-): ≤10 mg/kg
fluoride (F-): ≤10 mg/kg
sulfate (SO42-): ≤100 mg/kg

trazas de catión

As: ≤1 mg/kg
Cd: ≤1 mg/kg
Cu: ≤20 mg/kg
Fe: ≤10 mg/kg
Hg: ≤1 mg/kg
K: ≤50 mg/kg
Pb: ≤4 mg/kg
Zn: ≤10 mg/kg

idoneidad

complies for appearance of solution

cadena SMILES

O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O

InChI

1S/2Na.H3O4P.12H2O/c;;1-5(2,3)4;;;;;;;;;;;;/h;;(H3,1,2,3,4);12*1H2/q2*+1;;;;;;;;;;;;;/p-2

Clave InChI

DGLRDKLJZLEJCY-UHFFFAOYSA-L

¿Está buscando productos similares? Visita Guía de comparación de productos

Aplicación


  • Study of the Influence of Alkalizing Components on Matrix Pellets Prepared by Extrusion/Spheronization: This publication examines the effects of sodium phosphate dibasic dodecahydrate as an alkalizing agent in matrix pellets, showcasing its application in improving the physicochemical properties of pellets, which are crucial for controlled drug delivery systems (Hamedelniel EI, Bajdik J, Kasa P Jr, Pintye-Hodi K, 2012).

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 1

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Matthew H Crouthamel et al.
Arteriosclerosis, thrombosis, and vascular biology, 33(11), 2625-2632 (2013-08-24)
Elevated serum phosphate has emerged as a major risk factor for vascular calcification. The sodium-dependent phosphate cotransporter, PiT-1, was previously shown to be required for phosphate-induced osteogenic differentiation and calcification of cultured human vascular smooth muscle cells (VSMCs), but its
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
Luciano Candilio et al.
Heart (British Cardiac Society), 101(3), 185-192 (2014-09-26)
Remote ischaemic preconditioning (RIPC), using brief cycles of limb ischaemia/reperfusion, is a non-invasive, low-cost intervention that may reduce perioperative myocardial injury (PMI) in patients undergoing cardiac surgery. We investigated whether RIPC can also improve short-term clinical outcomes. One hundred and
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico